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Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10049-woman population-based
cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study
enrollment in 1993/1994 for HPV-16 (n¼9949), HPV-18 (n¼9928), HPV-31 (n¼9932), and HPV-45 (n¼3019). Seropositivity
was defined as five standard deviations above the mean optical density obtained for studied virgins (n¼573). HPV-16, -18, -31, and
-45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was
45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual
partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the
highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.
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Currently, detection of cervical human papillomavirus (HPV)
infection often relies on the identification of HPV DNA in
exfoliated cervicovaginal cells. However, because most HPV
infections (including oncogenic types) are transient and clear
within 2 years, HPV DNA detection is limited to identifying
current infections (Ho et al, 1995). The prevalence of HPV DNA
therefore underestimates the cumulative incidence of infection in a
population, particularly where the majority of women will not
develop persistent infection or cervical neoplasia. Measurement of
serum antibody to HPV capsids (or virus-like particles (VLPs)) has
been demonstrated as a useful although imperfect marker of past
and cumulative HPV exposure, thus complementing the assess-
ment of HPV DNA (Kirnbauer et al, 1994; Wideroff et al, 1995,
1999; Carter et al, 1996; Sasagawa et al, 1998; Touze et al, 2001).
As part of a large population-based study of the natural history
of HPV infection and cervical neoplasia in Guanacaste, Costa Rica,
we report here the population-based seroprevalence in Guanacaste
women of four oncogenic HPV types (HPV-16, -18, -31, and -45)
found in the majority of cervical cancers worldwide (Bosch et al,
1995; Munoz et al, 2003). The data presented document the
baseline burden of HPV exposure in Guanacaste, Costa Rica. As a
major objective, we determined the association of risk for
concurrent diagnosis of CIN3/cancer with HPV assessed jointly
by serology and PCR-based DNA testing. As only about half of all
HPV-DNA-positive women are seropositive using available VLP
assays (Kirnbauer et al, 1994; Le Cann et al, 1995), we also
investigated determinants of seropositivity in our population.
METHODS
Study population
This study was conducted in an on-going population-based cohort
study of 10049 women in Guanacaste, Costa Rica (Herrero et al,
1997; Hildesheim et al, 2001) who were enrolled in 1993–1994 with
the approval of the National Cancer Institute (NCI) and local
institutional review boards; all participants provided written
informed consent. Briefly, the cohort was a representative sample
of the adult population based on selection by cluster sampling,
with oversampling for cancer. Participation among eligible women
exceeded 90%, and participants completed a risk factor ques-
tionnaire that addressed demographic, behavioural, and sexual
practices. Women were screened using three cytologic and one
visual test at enrollment; colposcopy referral with biopsy was
performed for any abnormal or equivocal screening results of
suspicious lesions. For this analysis, a histologic diagnosis of CIN3 Received 29 May 2003; revised 18 July 2003; accepted 23 July 2003
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yor cancer (n¼107) was considered as the reference standard of
serious high-grade disease.
Serological measurements
Plasma samples collected at study enrollment were tested for anti-
HPV L1 antibodies at the Johns Hopkins Medical Institutions by a
VLP-based enzyme linked immunosorbent assay (ELISA) for HPV-
16, -18, -31, and -45. Of the 10077 women enrolled in the Costa
Rican cohort, results were obtained for VLP serologic responses to
HPV-16 (n¼9949), HPV-18 (n¼9928), HPV-31 (n¼9932), and
HPV-45 (n¼3019). Based on results from our on-going DNA
testing for the cohort, serologic testing for HPV-45 was
discontinued following 3040 assays due to the comparatively low
DNA prevalence (o1%).
HPV VLPs were prepared in Trichoplusia ni (High Fivet) cells
(Invitrogen, Carlsbad, CA, USA) from recombinant baculoviruses
expressing the L1 and L2 genes of HPV-16 or -31 or the L1 gene
alone of HPV-18 or -45. Virus-like particles were purified from cell
pellets by density-gradient ultracentrifugation and column chro-
matography techniques as described previously (Studentsov et al,
2002; Viscidi et al, 2003). For the VLP-based ELISA, 96-well flat
bottom PolySorp plates (Nunc, Naperville, IL, USA) were coated
overnight at 41C with 0.4–0.5mg total VLP protein per millilitre of
phosphate-buffered saline (PBS), pH 7.2. The plates were blocked
at room temperature for 3h with 0.5% (wtvol
 1) polyvinyl alcohol,
MW 30000–70000 (Sigma, St Louis, MO, USA) in PBS (0.5%
PVA). The blocking solution was replaced with PBS and the plates
were stored at  201C until use. Before use and following each
incubation step, the plates were washed four times with wash
solution (PBS-0.05% Tween 20) in an automatic plate washer
(Skanwasher 300, Skatron, Lier, Norway). Using a MultiPROBE II
robotic liquid handling system (Packard Instruments, Meriden,
CT, USA), plasma specimens were diluted 1:10 in 0.5% PVA and
10ml of the diluted plasma was added to the antigen-coated plate
containing 90ml of 0.5% PVA and incubated at 371C for 1h. After
extensive washing, antigen-bound immunoglobulin was detected
with horseradish peroxidase-conjugated goat anti-human IgG,
gamma chain specific (Zymed, San Francisco, CA, USA), diluted
1:4000 in 0.5% PVA, 0.025% Tween 20, 0.8% (wtvol
 1)
polyvinylpyrrolidone, MA 360000 (Sigma) in PBS. After 30min
at 371C, colour development was initiated by the addition of 2,20-
azino-di-(3-ethylbenzthiazoline-6-sulphonate) hydrogen peroxide
solution (Kirkegaard and Perry, Gaithersburg, MD, USA). The
reaction was stopped after 20min by addition of 1% dodecyl
sulphate and absorbance was measured at 405nm, with a reference
wavelength of 490nm, in an automated microtitre plate reader
(Molecular Devices, Menlo Park, CA, USA).
Specimens were tested in duplicate on separate plates, with
retesting of specimens with results exceeding a preset, acceptable
coefficient of variation (CV) of 25% if one of the replicate optical
density (OD) values was greater than the cut point for
seropositivity (40.05 OD units). Retesting by CV, however, did
not apply to samples where both OD values were lower than the
seropositivity cut point. Each batch comprised approximately
2000–3000 specimens, including both intrabatch and interbatch
reliability repeat specimens. Each batch also included specimens
from random samples of 200 of the 573 virgins in the study
population, which were used to calculate an ELISA cutoff.
HPV DNA testing
Cervical cytologic specimens were tested for HPV DNA using L1
MY09/MY11 consensus primer methods (Herrero et al, 2000;
Castle et al, 2002a). While HPV VLP measurements were
conducted on the entire cohort, HPV DNA measurements excluded
study virgins and women for whom pelvic exams were not
conducted (Hildesheim et al, 2001); HPV testing results were thus
available for 9165 women. Results were obtained for both HPV
DNA and VLP serologic responses to HPV-16 (n¼9112), HPV-18
(n¼9102), HPV-31 (n¼9105), and HPV-45 (n¼2774).
Statistical methods
Serology results were dichotomized as antibody positive or
negative. The cutoff was calculated independently for each test
batch, by comparison with the distribution of the values obtained
for the concurrently tested virgins in that batch (n¼200). We used
an iterative statistical approach that excluded outliers in the
distribution of virgin test results until no remaining value was
greater than two standard deviations above the mean optical
density of the virgin specimens in that batch. Seropositivity for
each HPV type was then defined as five standard deviations above
the mean OD obtained for the concurrently tested virgins (minus
virgin outliers). Alternative classifications of seropositivity using a
three standard deviation cutpoint, or a receiver operating curve
(ROC) approach contrasting the virgins to known type-specific
DNA positives yielded the same conclusions.
Overall, multiple-type, and single-type seroprevalence estimates
are reported. The seroreactivity of each HPV VLP type to the other
measured HPV types was determined by calculating and compar-
ing prevalence odds ratios (ORs). To assess possible antigenic
crossreactivity between types, prevalence ORs were calculated for
HPV seroreactivity and DNA status of the same or other HPV
types (HPV-16, -18, -31, -45). To further assess the type specificity
of the serologic assay, we calculated prevalence ORs for
seroreactivity of HPV-16, -18, -31, and -45 to DNA positivity of
HPV-6, -11, -26, -33, -35, -39, -40, -42, -51, -52, -53, -54, -55, -56,
-57, -58, -59, -61, -62, -66, -68, and -71.
To identify determinants of seropositivity, univariate associa-
tions for HPV-16, -18, and -31 seropositivity were assessed for the
following behavioural and reproductive variables: smoking (for-
mer, current, number of cigarettes), alcohol intake, early age at
first intercourse (defined as o16 years), number of sexual
partners (lifetime, and recently defined as within the last year),
number of pregnancies, number of live births, and use of oral
contraceptives (OC). Study virgins were excluded from these
analyses; we also do not report associations with HPV-45, due to
the discontinuation of this assay. Odds ratio estimates with 95%
confidence intervals were obtained to assess the magnitude and
statistical significance of the associations between HPV seroposi-
tivity and HPV DNA positivity, and to identify determinants of
HPV seropositivity; statistical significance was also obtained by w
2.
We included in our final multivariate model, variables statistically
significantly associated with seropositivity in our univariate
models: age (o25, 25–34, 35–44, 33–64, 65þ years), number
of lifetime sexual partners (1, 2–3, 4þ), age at first intercourse
(o16, 16–19, 20þ years), number of recent sexual partners (0, 1,
2þ), smoking (never, former, current), and OC use (never,
former, current).
To further characterise HPV exposure in the population, we
assessed exposure using both serological and DNA-based mea-
surements. We categorised exposure into four groups: (i) women
both HPV sero- and DNA-negative, (ii) women sero-positive but
DNA-negative, (iii) women sero-negative but DNA-positive, and
(iv) women both sero- and DNA-positive. For each HPV type, we
used logistic regression to assess the cross-sectional association
(OR with 95% confidence intervals (CI)) between HPV exposure
and CIN3/cancer, adjusted for age. All analyses were conducted on
SAS 8.2 for Windows.
RESULTS
The median age of the 9949 women for whom IgG antibodies to
HPV VLPs were measured was 38 years (range: 18–97 years).
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16, and 11%, respectively (Table 1). Of the 1533 women
seropositive for HPV-16, 579 (38%) were seropositive only for
HPV-16 and 954 (62%) were seropositive for HPV-16 in addition
to HPV-18 and -31. Similarly, for women seropositive for HPV-18,
-31, and -45, the minority (41, 39, and 27%) were seropositive only
for that type.
As more than 60% of seropositive women were seropositive for
multiple HPV types, we assessed type-specificity to distinguish
between true multiple infections and potential crossreactivity of
the assays. We assessed the association between seropositivity to
one HPV type and that to another type (Table 2). Seroreactivity to
HPV-16, -18, -31, or -45 was strongly associated with seroreactivity
to the other measured HPV types. Prevalence ORs appeared
similarly elevated, although highest for HPV-18 and -45 (OR: 14.9;
95% CI: 11.4–19.4), HPV-31 and -45 (OR: 10.3; 95% CI: 8.0–13.3),
and HPV-16 and -31 (OR: 8.5; 95% CI: 7.5–9.6). Analyses
restricted to single infections defined by concurrent DNA resulted
in diminished but still significant associations (data not shown).
To further clarify whether these associations reflect concomitant
infections, we calculated the association between HPV seroposi-
tivity and viral DNA positivity for the same type and for the three
other HPV types. As shown in Table 3, for all four HPV types
measured, the magnitude of the association was highest for each
HPV serotype and DNA of the same type. The prevalence OR for
HPV-16 seropositivity and HPV-16 DNA positivity was 4.5 (95%
CI: 3.6–5.6). For HPV-18, -31, and -45 seropositivity and DNA
positivity, the prevalence ORs were 2.7 (95% CI: 1.8–3.9), 5.1 (95%
CI: 3.6–7.3), and 3.0 (95% CI: 1.2–7.2), respectively. The type-
specificity of the serologic assay appeared weakest for HPV-18 and
-45. When analyses were restricted to single infections of the
specified HPV type by serology or by DNA, the magnitude of risk
for serology and DNA of the same type remained similarly
elevated, while the magnitude of association for serology and DNA
of a different type declined to null, although confidence intervals
were widened by reduced numbers. Moreover, when the analyses
were restricted to HPV-exposed women, defined as either HPV
DNA- or sero-positive for any of the four HPV types measured,
thus reducing confounding due to (levels of relevant) sexual
behaviour, the magnitude of association for HPV DNA and
serology of the same type became much stronger. Again, CIs were
widened due to reduced numbers. We also assessed the association
between HPV-16, -18, -31, and -45 seropositivity with other HPV
DNA types for which data were available (HPV-6, -11, -26, -33, -35,
-39, -40, -51, -52, -53, -54, -55, -56, -58, -59, -61, -66, -68, -70, -71,
-73); null associations largely were observed between HPV
seropositivity with these other HPV types (data not shown),
supporting type-specificity of the four serologic assays.
In our population, HPV seroprevalence was significantly higher
than HPV DNA prevalence, which was 3.5% for HPV-16, 1.3% for
HPV-18, 1.4% for HPV-31, and 0.8% for HPV-45. As described in
the Methods section, HPV DNA was not measured in study virgins;
therefore, with the assumption that virgins are HPV DNA-negative
(Kjaer et al, 2001), the HPV DNA prevalence rates would be even
lower. Of women HPV DNA-positive for each respective type, 45%
were seropositive for HPV-16, 34% were seropositive for HPV-18,
51% were seropositive for HPV-31, and 28% were seropositive for
HPV-45, thus reflecting the understanding that not all women
infected with HPV will seroconvert, as defined within the detection
limits of our assays and our stringent cutpoint. Conversely, of
women seropositive for HPV-16, only 10% were HPV DNA-
positive; for HPV-18, -31, and -45 seropositive women, DNA
positivity for their same HPV type was 3, 4, and 2%, respectively,
reflecting the transient nature of HPV infection.
HPV seroprevalence and DNA prevalence by age are shown in
Figure 1. At all ages, HPV seroprevalence of all four types
remained elevated compared to DNA positivity. HPV seropreva-
lence reached its highest peak at 25–34 years for HPV-31 and at
35–44 years for HPV-16, -18, and -45. Although seropositivity
appeared to decline slightly with age after its peak, seroprevalence
always remained elevated above the level seen in women less than
25 years old. In contrast, HPV DNA positivity peaked for the four
HPV types in women less than 25 years old and declined with
increasing age; for HPV-16, however, there appeared to be a slight
secondary increase in DNA prevalence in the older age groups. It is
important to note again that these data for HPV DNA positivity do
not include virgins, the majority of whom were less than 25 years
(64%) or 25–34 years (20%).
To identify determinants of HPV seropositivity, we assessed the
association between demographic, social, and behavioural risk
factors with HPV-16, -18, and -31 seropositivity in sexually active
women (thus excluding virgins). Of all demographic and
behaviuoral risk factors measured in univariate analyses, age,
number of recent and past sexual partners, age at first intercourse,
smoking, and OC use were statistically significantly associated with
HPV seropositivity, and we therefore included them in our final
multivariate model. As shown in Table 4, there was a clear stepwise
increase in prevalence and association with seropositivity for all
four HPV types with increasing number of lifetime sexual partners.
In our final model, the number of recent sexual partners, defined
as within the past year, was no longer associated with HPV-16
seropositivity. Since having two or more recent partners was
highly correlated with a high lifetime number of sexual partners,
there was likely confounding by past exposure. Finally, for women
who initiated sexual intercourse at older ages, statistically
Table 1 Seroprevalence of HPV-16, -18, -31, and -45 in the Costa Rican
population-based cohort
HPV type Seroprevalence
Only this
type
This plus
other type
a
16 (n¼9949) 1533 (15.4%) 579 (5.8%) 954 (9.6%)
18 (n¼9928) 1537 (15.5%) 626 (6.3%) 911 (9.2%)
31 (n¼9932) 1638 (16.5%) 643 (6.5%) 995 (10.0%)
45 (n¼3019) 335 (11.1%) 91 (3.0%) 244 (8.1%)
aOther defined as HPV-16, -18, and -31. HPV-45 was not included due to
termination of assay.
Table 2 Prevalence ORs and 95% CIs of HPV-16, -18, -31, and -45
seroreactivity vs seroreactivity to other type
HPV type by serology
HPV type 16 18 31
by serology OR (95% CI) OR (95% CI) OR (95% CI)
18 7.0 (6.2–7.9)
31 8.5 (7.5–9.6) 7.1 (6.3–8.0)
45 6.6 (5.1–8.4) 14.9 (11.4–19.4) 10.3 (8.0–13.3)
Table 3 Prevalence ORs and 95% CIs of HPV-16, -18, -31, and -45
seroreactivity vs DNA-type positivity of the same type
HPV type by serology
HPV type 16 18 31 45
by DNA OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
16 4.5 (3.6–5.6) 1.9 (1.5–2.5) 2.0 (1.6–2.6) 1.0 (0.5–2.0)
18 1.6 (1.0–2.4) 2.7 (1.8–3.9) 1.9 (1.3–2.8) 2.5 (1.0–6.4)
31 2.6 (1.8–3.8) 2.2 (1.5–3.2) 5.1 (3.6–7.3) 1.8 (0.8–4.0)
45 2.1 (1.3–3.6) 1.7 (1.0–3.0) 2.4 (1.5–4.0) 3.0 (1.2–7.2)
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18, and -31 seropositivity; this is likely due to the decreased
lifetime number of sexual partners that is correlated with those
initiating sexual intercourse at older ages.
As shown in Table 4, current smoking exhibited a borderline
association with HPV-16 seropositivity, with a risk of 1.2 (95% CI:
1.0–1.5); former and current OC use were associated with HPV-16
seropositivity with risks of 1.3 (95% CI: 1.1–1.5) and 1.5 (95% CI:
1.2–1.8), respectively. No association was demonstrated between
HPV-18 seropositivity and smoking, but borderline associations
were observed for current OC use, and between HPV-31
seropositivity and former OC use. Taken together, these results
support the role of sexual behaviour as the key determinant of
HPV seropositivity; the HPV cofactors for cervical cancer, namely
OC use, may play a minor role in the risk of HPV-16 seropositivity.
Determinants for combined HPV-16, -18, or -31 seropositivity
similarly included number of lifetime sexual partners and age at
first intercourse. However, neither smoking nor OC use was
associated with combined seropositivity (data not shown).
We assessed the risk of CIN3/cancer associated with HPV
exposure as determined by HPV DNA and serology measurements
for HPV-16, -18, and -31. As shown in Table 5, HPV-16 DNA-
positive women possessed the greatest magnitude of risk for CIN3/
cancer, regardless of serologic status, with age-adjusted ORs of
34.7 (19.7–61.0) for women both HPV-16 DNA- and sero-positive,
and 39.9 (05% CI: 24.1–66.2) for women only HPV-16 DNA-
positive. Women only seropositive for HPV-16 possessed a much
lower, but still significantly elevated level of risk for CIN3/cancer,
with OR of 2.0 (age-adjusted OR: 1.1–3.7). For HPV-18 and -31,
the magnitude of association for women both DNA- and sero-
positive with CIN3/cancer was the highest, followed by women
0
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Figure 1 Age distribution of HPV-16, -18, -31, and -45 seroprevalence*
and DNA-prevalence** in Guanacaste, Costa Rica women. *Population-
based HPV-16, -18, -31, and -45 serology prevalence is shown in black lines
and includes study virgins. Black dotted lines denote seroprevalence
excluding study virgins. **HPV DNA prevalence does not include study
virgins.
Table 4 Final logistic regression model demonstrating association between number of lifetime sexual partners, age at first sexual intercourse, smoking, OC
use and HPV-16, -18, and -31 seropositivity, also adjusted for age and recent sexual partners (excluding study virgins)
HPV-16 seropositive HPV-18 seropositive HPV-31 seropositive
# (%) OR (95% CI) # (%) OR (95% CI) # (%) OR (95% CI)
Age
o25 166 (15.7) — 134 (12.7) — 179 (16.9) —
25–29 182 (14.2) 0.9 (0.7–1.1) 176 (13.7) 1.1 (0.8–1.4) 235 (18.3) 1.1 (0.9–1.4)
30–44 657 (18.4) 1.1 (0.9–1.4) 645 (18.1) 1.4 (1.2–1.7) 667 (18.7) 1.1 (0.9–1.3)
45–64 361 (15.0) 0.9 (0.7–1.2) 402 (16.7) 1.3 (1.0–1.7) 369 (15.3) 0.8 (0.7–1.0)
65+ 143 (13.7) 0.9 (0.7–1.2) 157 (15.0) 1.3 (0.9–1.7) 152 (14.6) 0.8 (0.6–1.1)
Lifetime number of sexual partners
1 (referent) 537 (10.6) — 557 (11.0) — 646 (12.8) —
2–3 654 (20.3) 2.1 (1.8–2.3) 660 (20.5) 2.0 (1.7–2.2) 656 (20.4) 1.7 (1.5–1.9)
4+ 318 (28.9) 3.1 (2.6–3.7) 297 (27.0) 2.6 (2.2–3.1) 300 (27.2) 2.3 (2.0–2.8)
Number of recent sexual partners
0 297 (16.0) — 315 (17.0) — 305 (16.4) —
1 1153 (15.8) 0.9 (0.8–1.1) 1134 (15.6) 0.9 (0.8–1.1) 1235 (16.9) 0.9 (0.8–1.1)
2+ 58 (26.9) 0.9 (0.6–1.3) 65 (30.1) 1.3 (0.9–1.8) 60 (27.8) 1.0 (0.7–1.5)
Age at first intercourse
o16 (referent) 415 (21.1) — 419 (21.4) — 403 (20.5) —
16–19 726 (15.7) 0.8 (0.7–1.0) 718 (15.5) 0.8 (0.7–0.9) 816 (17.6) 1.0 (0.8–1.1)
20+ 367 (13.3) 0.8 (0.7–1.0) 376 (13.6) 0.8 (0.6–0.9) 382 (13.8) 0.8 (0.7–1.0)
Smoking
Never (referent) 1285 (15.5) — 1304 (15.7) — 1380 (16.6) —
Former 111 (19.6) 1.2 (0.9–1.4) 105 (18.5) 1.0 (0.8–1.3) 114 (20.1) 1.2 (0.9–1.5)
Current 113 (22.9) 1.2 (1.0–1.5) 103 (20.9) 1.1 (0.8–1.3) 107 (21.7) 1.1 (0.9–1.4)
Oral contraceptive use
Never (referent) 511 (13.9) — 553 (15.1) — 570 (15.5) —
Former 671 (17.0) 1.3 (1.1–1.5) 683 (17.4) 1.2 (1.0–1.4) 708 (18.0) 1.1 (1.0–1.3)
Current 326 (18.5) 1.5 (1.2–1.8) 277 (15.7) 1.2 (1.0–1.4) 324 (18.4) 1.1 (0.9–1.3)
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sessed a moderate increase in risk for CIN3/cancer with an age-
adjusted OR of 1.9 (95% CI: 1.2–3.0); women only seropositive for
HPV-31 also possessed an increase in risk for CIN3/cancer (age-
adjusted OR: 1.7; 95% CI: 1.1–2.7). Of CIN3/cancers seropositive
for either HPV-16, -18, or -31, and DNA-negative for the respective
type, the majority were also DNA-positive for another measured
oncogenic HPV type at the time of the serological measurement,
although it is unknown whether these are the same HPV types
found in the tumour. When the analyses are restricted to single
infections as defined by seropositivity, the magnitudes of
association were slightly diminished for women seropositive but
DNA-negative for HPV-31, but stayed constant for HPV-16 and -18
seropositivity.
We also conducted analyses stratified by age to delineate clearly
risk relationships among young women, because past and recent
exposures are likely equivalent in this age group. For women less
than 25 years of age, the highest level of risk for CIN3/cancer was
observed for HPV-16 DNA-positive women (OR¼41.9) rather
than DNA- and sero-positive women (OR¼26.2). Higher risk
estimates in DNA-positive women less than 25 years of age were
also demonstrated for HPV-18. No statistically significant associa-
tions were observed between women HPV seropositivity only and
CIN3/cancer for women less than 25 years of age. Exclusion of
women less than 25 years of age did not significantly change the
results.
DISCUSSION
Overall, the HPV seroprevalence of 15–16% in our population is
consistent with the broad range (10–52%) found in previous
reports (Nonnenmacher et al, 1996; Hagensee et al, 1999; Stone
et al, 2002). HPV-16 alone accounts for approximately half of all
cervical cancers in Guanacaste (Herrero et al, 2000) and worldwide
(Munoz et al, 2003); likewise, the population-based prevalence of
HPV-16 DNA positivity is highest in our cohort. However, this
predominance of HPV-16 is not reflected in seroprevalence, and
the overall and age-specific seroprevalence of HPV-16, -18, and -31
are equivalent, despite the known differences between these
HPV types. The reason for the difference between type-specific
DNA prevalence and seroprevalence is unclear. We used a
stringent cutoff for defining seropositivity, which probably
underestimated the seroprevalence in our population. However,
the potential for assay crossreactivity may have resulted in an
opposite effect of overestimating seroprevalence. Based on our
analyses, we believe that these magnitudes of risk reflect multiple
infections in our population, but crossreactivity cannot be
ruled out. Although magnitudes of risk appeared highest for
related HPV types (e.g., HPV-16 and -31, HPV-18 and -45), they
were also not exclusive to related types (e.g., HPV-31 and -45). One
possible explanation for the discrepancy between DNA- and
sero-positivity may be the differential incidence and duration of
type-specific HPV.
The differential peaks for HPV DNA- and sero-prevalence are of
interest. It is well understood that high DNA positivity rates in
young women are due to sexual activity. While HPV seroconver-
sion can take up to 18 months (Carter et al, 1996, 2000), in
Guanacaste, seroprevalence peaked 10–20 years later. This decade-
long lag time is probably due to the low seroconversion rate and/or
the potential need for repeated exposures and thus, antigenic
stimulation, to induce a detectable antibody response. The
simultaneous increase in seroprevalence and decline in DNA
prevalence in women over 25 years of age may indicate that these
women continue to be exposed to HPV as a result of repeated or
recurrent infection or reactivation of latent infection, but that
levels of viral replication are below the detection limit of PCR.
However, the slight secondary increase in HPV-16 DNA prevalence
in the older age groups is noted and previously reported (Herrero
et al, 2000). The seroprevalence peak is also 10–20 years after
sexual initiation, thus potentially mirroring the effect of multiple
lifetime sexual partners, which correlates with age. However,
unlike other studies, we did not observe an increase in HPV
seropositivity with age (Strickler et al, 1999; Studentsov et al,
2002). On the contrary, the slight decrease of seropositivity
observed in our older age groups supports the suggested waning of
seropositivity over time and the imperfect nature of serology as a
measure of cumulative exposure; alternatively, this could reflect a
cohort effect.
The moderate overall agreement between HPV seropositivity
and DNA positivity in our study is consistent with other studies
(Olsen et al, 1996), further confirming that only a subset of women
exposed to HPV will seroconvert. Although we comprehensively
assessed demographic, social, and behavioural variables to identify
determinants of seropositivity, our findings support the single
overriding factor to be exposure to HPV as measured by past
sexual activity, as others have observed (Dillner et al, 1996;
Andersson-Ellstrom et al, 1996; Wideroff et al, 1996; Kjellberg et al,
1999; Kjaer et al, 2001; Castle et al, 2002b;). Our data shown in
Table 4 demonstrate that for HPV-16, -18, and -31, there are
stepwise increases in risk of CIN3/cancer with increasing lifetime
number of sexual partners, and decreases in risk of CIN3/cancer
with increasing age of first sexual intercourse. These associations
were also clearly observed in our subset of women with HPV-45
Table 5 Association between differential exposures (by serology and DNA) and disease outcome of CIN3/cancer, adjusted by age
HPV Serology DNA Total n
a CIN3/cancer n (%)
CIN3/cancer positive for
another oncogenic type OR (95% CI)
16 + + 144 21 (14.6) 4 34.7 (19.7–61.0)
  + 179 30 (16.8) 6 39.9 (24.1–66.2)
+   1333 15 (1.1) 11 2.0 (1.1–3.7)
   7456 41 (0.5) 32 1.0
18 + + 41 5 (12.2) 3 16.6 (6.3–43.9)
  + 80 8 (10.0) 3 13.6 (6.3–29.6)
+   1436 25 (1.7) 21 1.9 (1.2–3.0)
   7545 68 (0.9) 59 1.0
31 + + 63 7 (11.1) 3 14.1 (6.2–32.2)
  + 61 3 (4.9) 2 5.7 (1.7–18.7)
+   1502 25 (1.7) 21 1.7 (1.1–2.7)
   7479 72 (1.0) 63 1.0
aTotal n¼9112; HPV-18 and HPV-31 exposure groups do not add up to 9112 due to missing data.
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yserology measurements. Only for HPV-16 seropositivity were the
additional determinants, OC use, found to be statistically
significant; these were borderline to not statistically significant
for HPV-18 and -31 seropositivity. For HPV-16, our results
support those by Stone et al (2002), who also demonstrate elevated
risk of HPV-16 seropositivity with OC use (ever). Although Shin
et al (2003) demonstrated a modest association between smoking
and HPV seropositivity, the associations for HPV-16, -18, and -31
in our data were borderline or null. The effects of these cofactors,
even if real, are likely modest at best.
A number of studies have supported the use of HPV-16 VLP as a
biomarker of past HPV exposure, with moderate associations
between HPV seropositivity and cervical cancer (Nonnenmacher
et al, 1995; Dillner et al, 1996). As previously reported, the
magnitude of association between seropositivity and cervical
cancer in this study were 2–3-fold compared to HPV seronegative
women (Nonnenmacher et al, 1995; Chua et al, 1996; Dillner et al,
1996, 1997; Wideroff et al, 1996; Wang et al, 2000; Sigstad et al,
2002). Our stratified analyses clearly demonstrated that HPV DNA-
positive women had the highest levels of risk for CIN3/cancer; for
HPV-18 and -31, risk for CIN3/cancer was highest for women both
HPV DNA- and sero-positive followed by women DNA-positive
only. While we observed a moderate risk of two-fold for HPV-16,
-18, and -31 seropositivity in the absence of HPV DNA positivity in
cross-sectional analyses, the majority of these women were
seropositive (HPV-16, -18, -31, or -45) or DNA-positive for
another measured oncogenic HPV type. However, to assess reliably
whether the independent association between seropositivity and
disease was confounded by HPV infection would require HPV
typing in the histologic tissue. Finally, although previous studies
have reported an increasing association of HPV seropositivity with
disease severity (De Sanjose et al, 1996; Heim et al, 2002), this was
not observed in our study. Stratification of disease by CIN1, CIN2,
CIN3, and cancer did not demonstrate a stepwise increase in
association, although risk for CIN3 and cancer did exceed that for
CIN1 and CIN2 (data not shown).
To our knowledge, this is the largest population-based
seroprevalence study of the four major HPV types: HPV-16, -18,
-31, and -45; subjects were representative of the adult female
population of Guanacaste, Costa Rica. Although serology measure-
ments underestimate cumulative exposure to HPV due to low
seroconversion and possibly waning seropositivity over time,
detection of serum VLP antibodies to HPV nevertheless provides
an informative assessment of HPV exposure in a population. To
understand the implications of HPV serology in the natural history
of cervical cancer, however, will require prospective studies.
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